Two prospective trials of immunotherapy in thyroid cancer, one of them negative, provided support for precision-medicine approaches that include immunotherapy. The studies were reported simultaneously ...

Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer Adult-onset neuroblastoma ...

Please provide your email address to receive an email when new articles are posted on . An updated guideline for best practices in managing anaplastic thyroid cancer stresses the need for ...

Overall survival rates for adults diagnosed with anaplastic thyroid carcinoma are similar between those with a history of cancer and those with no previous cancer diagnosis, according to findings ...

Anaplastic thyroid carcinoma is one of the most aggressive and deadly cancers in humans and accounts for one to two cases per million persons annually. The rarity of this malignancy and the rapidity ...

NATICK, Mass.--(BUSINESS WIRE)--AffyImmune Therapeutics, a clinical-stage biotechnology company committed to developing novel, first-in-class CAR T cell therapies, today announced early results from a ...

LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the anaplastic thyroid cancer market. The report includes a detailed analysis of the pipeline molecules under ...

Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge. A recent review published in Genes & Diseases offers a comprehensive ...

WASHINGTON ― Adding the PD-1 inhibitor pembrolizumab to the established combination of dabrafenib and trametinib (DT) significantly improves survival outcomes in BRAF V600E-mutated anaplastic thyroid ...